MAPK1 and neoplasm: Ipatasertib was tested in combination with other signaling pathway inhibitors along the RAS-RAF-MEK-ERK pathway and along the PI3K-AKT-mTOR pathway in doublets in patient-derived human tumor cell lines and well-established human tumor cell lines in mct-spheroids.